New promising indicators of response to ICIs, such as the post-pembrolizumab fold-change of Ki67+ PD-1+ CD8 T cells relative to tumor burden [21], CD28 expression on CD8 T cells [22] will be considered in future analyses. This evidence concerns the gene MKI67 and neoplasm.